drugset
Drugs / IL15-transpresenting WT1-targeted Dendritic Cell Vaccine
last change Sep 2025 re-read 3 minutes ago

IL15-transpresenting WT1-targeted Dendritic Cell Vaccine

Vaccine targets WT1

Developed for
esophageal cancer · liver cancer · malignant pancreatic neoplasm · ovarian cancer
Investigated by
Kom Op Tegen Kanker · Stichting tegen Kanker · University Hospital, Antwerp

Trials 1

today NCT05964361 · Ph 1/2
202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05964361 Dec 2023 → Sep 2025 esophageal cancer, liver cancer, malignant pancreatic neoplasm, ovarian cancer University Hospital, Antwerp Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as IL15-transpresenting WT1-targeted Dendritic Cell Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT05964361 ↗
Modality Vaccine “dendritic cell vaccine” NCT05964361 ↗
Target WT1 “target the tumor antigen Wilms' Tumor-1 (WT1)” NCT05964361 ↗